Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

While first-generation glucagon-like peptide-1 receptor agonists have clearly taken the obesity market by storm, generating billions of dollars for Novo Nordisk A/S and Eli Lilly and Co., several ...

If you are looking to invest in top growth stocks, these companies can experience more volatility than the average stock. Here are two top growth stocks to consider buying right now. Eli Lilly (NYSE: ...

Wall Street is bullish on Viking, but the company still has a lot to prove. Viking has a number of different clinical studies ...

Eli Lilly (NYSE: LLY) has been in the limelight more frequently of late, with the success of its glucagon-like peptide-1 (GLP-1) drugs that have reinvigorated growth for one of the oldest ...

Yet the soaring enthusiasm for so-called glucagon-like peptide-1 receptor agonists ... Novo Nordisk and Eli Lilly. All That Glitters Is Not Gold: Issues and Risks Around GLP-1 Medications The ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Aadvark, which will list on the Nasdaq under the ticker “AARD” Feb. 13, will have the opportunity to bring in roughly $14.1 ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...